Pankaj Patel's Cadila receives approval from USFDA, stock sizzles

One of the leading pharmaceutical companies in India and also a global healthcare provider, Ahmedabad-based Zydus Cadila Healthcare has received a final approval from the US Food and Drug Administration (USFDA) to market Methotrexate Tablets USP, 2.5 mg. The drug which is helpful in curing leukemia, lymphoma, breast cancer, lung cancer and other cancers, will be produced at group formulation manufacturing plant in Ahmedabad Pharma Special Economic Zone (SEZ).

Meanwhile, Zydus Cadila Healthcare is also trending for its stock gain of 1.63 per cent on Wednesday. The stock of the company is trading with a Simple Moving Average (SMA) of 364.38. In the last one year, the stock has surged by 18.09 per cent.